This study tests a new drug, **VY7523**, to help people with early Alzheimer's Disease (AD), a condition affecting the brain and memory. The study checks if the drug is safe and how it works. Some participants will receive the drug while others will get a placebo, a harmless pill that has no effect, to compare results. The study lasts up to 6 months for lower doses and 18 months for the highest dose. Alzheimer's Disease (AD) is when the brain loses its ability to remember things and think clearly.

• **Study Duration**: Up to 18 months, depending on the dose group.
• **Participation Requirements**: You must have early AD and an informant/caregiver to help.
• **Compensation and Risks**: Details about compensation and risks will be provided during the study enrollment process.

Participants must have a caregiver, be healthy except for AD, and be on a stable dose of any current AD treatment. People with certain health issues, like strokes or seizures, or taking specific AD drugs cannot join. The study includes several clinic visits, and your caregiver must attend as well.